On Aug. 20, 2019, Bayer announced that it has entered into a definitive agreement with US-based Elanco Animal Health to sell its Animal Health business to Elanco in a transaction valued at $7.6 billion. The purchase price consists of $5.3 billion in cash, subject to customary purchase price adjuOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.